Navigation Links
TeraDiscoveries to Use its Inverse Design Software Running on Windows Azure to Advance Its Computational Drug Discovery Process
Date:4/23/2012

RESEARCH TRIANGLE PARK, N.C., April 23, 2012 /PRNewswire/ -- TeraDiscoveries, Inc., announced today a strategic relationship with Microsoft Corp. that will help it extend the reach of its drug discovery process. Microsoft is providing support and cloud computing time on Windows Azure that TeraDiscoveries will apply to identify inhibitors of 25 biological targets.

TeraDiscoveries will use its Inverse Design software that runs computational models to quickly scan virtual chemical libraries to find the strongest inhibitors of a specific biological target. The process identifies novel drug candidates that feature good clinical trial properties and demonstrate low probability of toxic side effects.

"Designing new drugs that bind to a specified protein target requires finding the best molecule in a vast chemical space. Our approach searches this space much more efficiently and cost-effectively than traditional methods," says Ed Addison, CEO of TeraDiscoveries. "Our strategic relationship with Microsoft enables us to partner with smaller pharmaceutical or medical research companies in the pursuit of these molecules."

"Windows Azure is an open and flexible cloud platform that has the scale and reliability to enable the type of computing power needed by software like Inverse Design," says Doug Hauger, General Manager, Windows Azure Business Development, Microsoft. "We're pleased to be able to support the work done by TeraDiscoveries to help advance its drug discovery process."

Companies can license Inverse Design and run it on Windows Azure to design, discover, or optimize new small molecule or peptide drugs for their targets. TeraDiscoveries also provides drug discovery services for companies seeking outside assistance.

TeraDiscoveries will be presenting Inverse Design in booth MP-10 at the Bio-IT World Conference & Expo taking place April 24 to 26, 2012, in Boston.

About TeraDiscoveries, Inc.

TeraDiscoveries is a drug discovery company located in Research Triangle Park, North Carolina. The company's Inverse Design software enables a paradigm shift to dramatically improve upon traditional drug discovery and design methods. This proprietary software combined with cloud computing enables the rapid and accurate discovery of novel drug candidates to serve as a catalyst for improved health and well-being. Visit www.teradiscoveries.com or contact Ed Addison at eaddison@teradiscoveries.com or (910) 398-1200.  

All product and company names herein may be trademarks of their respective owners.


'/>"/>
SOURCE TeraDiscoveries, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Inverseons Founder and SAB Member Published in PNAS
2. Inverseon Announces Positive Phase IIa Asthma Study
3. TissuGlu® Surgical Adhesive Named 2012 Medical Design Excellence Awards Finalist
4. Ultragenyx Granted Orphan Designations in Europe for Two Lead Product Candidates, UX001 for HIBM and UX003 for MPS 7
5. GlobalSpec Medical Equipment Design Online Trade Show and Event Draws More Than 1,100 Attendees
6. Brainlab Curve Wins Coveted Red Dot Award: Product Design 2012
7. Government Rule Designed to Limit CT Scans in ERs Is Unreliable, Invalid and Inaccurate, Says ACEP
8. Sensors in Design Summit Launches at Design West
9. Medical Design & Manufacturing Conference to be Launched in Texas in March 2012
10. CSL Behring Receives FDA Orphan Drug Designation for rVIIa-FP, a Novel Therapy in Development to Treat Hemophilia A and Hemophilia B Patients Who Have Inhibitors
11. Nationally Recognized Glenveigh Medical Announces Orphan Drug Designation for Treatment for Severe Preeclampsia and Eclampsia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... 2016 According to a ... by Product (Instruments, Reagents, Software), Technology (Immunoassay, Clinical ... Nephrology, Infectious Diseases) - Forecast to 2021" published ... USD 60.22 Billion in 2016. This market is ... during the forecast period (2016-2021) to reach USD ...
(Date:12/2/2016)...  The Addiction Treatment Advisory Group (ATAG), created ... Pharmacy (AMCP), has released detailed findings on how ... addiction crisis, including through improved access to naloxone ... newly released paper, "The Role of Managed Care ... issues around gaps and barriers to addiction treatment ...
(Date:12/2/2016)... -- Boston Scientific Corporation (NYSE: BSX ) ... assets and capabilities of the Neovasc, Inc., (NASDAQ: ... as well as a 15% equity stake in Neovasc, ... Neovasc advanced biological tissue business makes elements used in ... System. * Upon completion of the transaction, the ...
Breaking Medicine Technology:
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... On Dec. ... the Hard Rock Hotel San Diego honoring the 2016 MPN Heroes—eight individuals who have ... (MPNs) by going above and beyond the standard of care, demonstrating leadership within the ...
(Date:12/2/2016)... ... ... Advanced Inc., a leading provider of travel therapy and travel nursing across ... Advanced Inc.’s Chief Financial Officer, effective December 1, 2016. Jason previously served as Vice ... leadership experience to Advanced Inc. He began his career in finance at Ernst & ...
(Date:12/2/2016)... Raleigh, NC (PRWEB) , ... December 02, 2016 , ... ... the Open Enrollment Period (or Annual Election Period), is ending December 7th. Currently-enrolled Medicare ... plan (Part C) or prescription drug plan (Part D) need to make changes during ...
(Date:12/2/2016)... , ... December 02, 2016 , ... ... interview of two ostomy patients, standing as living proof that attitude and determination ... digestive diseases and issues that spike around the holidays. This campaign will offer ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... Health" in USA Today, which covers the innovative treatments, therapeutic technologies, and revolutionized ... fulfilling lives. “We are prolonging life 6 years in the last 3 decades,” ...
Breaking Medicine News(10 mins):